SCHEMBL6170071

SCHEMBL6170071

CCN(C(=O)c1ccc([N+](=O)[O-])cc1I)c1ccccc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.61
TRPM8 Q7Z2W7 1/20 0.52
SMN1; SMN2 Q16637 2/20 0.51
TP53 P04637 2/20 0.49
HTT P42858 1/20 0.46
TSHR P16473 2/20 0.44
RAB9A P51151 2/20 0.44
NPC1 O15118 1/20 0.44
GLA P06280 1/20 0.44
ATM Q13315 2/20 0.44
S1PR4 O95977 1/20 0.44
LMNA P02545 1/20 0.44
CYP3A4 P08684 2/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
RECQL P46063 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
MEN1 O00255 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6171862 0.82 ALDH1A1 (0.61) ALDH1A1TRPM8SMN1; SMN2TP53HTT
SCHEMBL6170159 0.79 TSHR (0.64) ALDH1A1SMN1; SMN2TP53HTTTSHR
SCHEMBL7376588 0.79 ALDH1A1 (0.89) ALDH1A1TRPM8SMN1; SMN2TP53HTT
SCHEMBL10525429 0.78 ALDH1A1 (0.72) ALDH1A1TRPM8SMN1; SMN2TP53HTT
SCHEMBL1418030 0.73 CES2 (0.54) ALDH1A1TRPM8SMN1; SMN2HTTATM
SCHEMBL7055735 0.73 CES2 (0.54) ALDH1A1TRPM8SMN1; SMN2HTTATM
Methyl Alcohol SCHEMBL28179970 0.73 CES2 (0.54) ALDH1A1SMN1; SMN2TP53HTTRAB9A
SCHEMBL1024380 0.73 ALDH1A1 (0.64) ALDH1A1SMN1; SMN2TP53HTTLMNA
SCHEMBL27278834 0.73 CES2 (0.56) ALDH1A1SMN1; SMN2TP53HTTRAB9A
SCHEMBL5779054 0.72 L3MBTL1 (0.48) ALDH1A1SMN1; SMN2TP53HTTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6958347-B2 Aminophenanthridinone and aminophenanthridine as NPY-5 antagonists PFIZER INC. (US) 2005-10-25 US disclosed
EP-1578728-A1 5-AMINOPHENANTHRIDINE DERIVATIVES AS NPY-5 ANTAGONISTS Pfizer Products Inc. (US) 2005-09-28 EP disclosed
WO-2004054981-A1 5-AMINOPHENANTHRIDINE DERIVATIVES AS NPY-5 ANTAGONISTS PFIZER PRODUCTS INC. (US) 2004-07-01 WO disclosed
US-20040122038-A1 NPY-5 antagonists PFIZER INC 2004-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040122038-A1 NPY-5 antagonists NPY5R, NPY1R, NPY2R ALDH1A1 2832/4885TRPM8 831/4885SMN1; SMN2 1679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.